Joshua Zeidner: Magrolimab plus Azacitidine vs Physician Choice in Newly Diagnosed TP53-mut AML
Joshua Zeidner, Associate Professor at UNC Lineberger, shared on X about recent paper he and colleagues co-authored, titled “Magrolimab plus azacitidine vs physician’s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study” published on Blood.
Authors: Joshua F. Zeidner, David A. Sallman, Christian Récher, Naval G. Daver, Anskar YH Leung, Devendra K. Hiwase, Marion Subklewe, Thomas Pabst, Pau Montesinos, Richard A Larson, Lindsay Wilde, Anoop K. Enjeti, Ichiro Kawashima, Cristina Papayannidis, Jenny O’Nions, Lisa Johnson, Mei Dong, Julie Huang, Taravat Bagheri, Gal Hacohen-Kleiman, Calvin Lee, Paresh Vyas
“Hot Off the Press ENHANCE-2- Randomized P3 Study of Aza/Magrolimab vs Physician Choice in Newly Dx TP53-mut AML- published in Blood. We desperately need novel Tx’s for TP53 mut AML, disappointing results but critical info for future studies.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023